The second approach is targeting mechanisms of resistance to anti-PD1/ anti-PD-L1 therapy identified in pre-clinical research, such as tumor-infiltrating Treg cells [39, 119], epigenetic control of immune function [120, 121], and other immune-related signaling pathways [122]. Here, CD274 is linked to neoplasm.